Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Inventory (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Inventory for 5 consecutive years, with $351.0 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 11.12% to $351.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $351.0 million through Dec 2025, up 11.12% year-over-year, with the annual reading at $351.0 million for FY2025, 11.12% up from the prior year.
  • Inventory hit $351.0 million in Q4 2025 for Ascendis Pharma A, up from $315.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $351.0 million in Q4 2025 to a low of $86.3 million in Q4 2021.
  • Historically, Inventory has averaged $222.3 million across 5 years, with a median of $224.8 million in 2023.
  • Biggest five-year swings in Inventory: skyrocketed 68.62% in 2023 and later rose 11.12% in 2025.
  • Year by year, Inventory stood at $86.3 million in 2021, then skyrocketed by 54.55% to $133.3 million in 2022, then surged by 68.62% to $224.8 million in 2023, then soared by 40.52% to $315.9 million in 2024, then grew by 11.12% to $351.0 million in 2025.
  • Business Quant data shows Inventory for ASND at $351.0 million in Q4 2025, $315.9 million in Q4 2024, and $224.8 million in Q4 2023.